| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income (loss) | -90,469 | 47,015 | 275,506 | 179,406 |
| Deferred taxes | -175 | 0 | 36 | -68 |
| Net realized gain on sale of financial instruments | 1,302 | 131 | 119 | -2 |
| Depreciation and amortization expense | 21,012 | 13,700 | 6,730 | 22,912 |
| Amortization of debt issuance costs | 774 | 389 | 194 | 583 |
| Stock-based compensation expense | 69,569 | 49,084 | 24,975 | 83,969 |
| Net accretion of investments | 23,066 | 15,667 | 7,673 | 18,956 |
| Change in provision for credit losses | -24,020 | -23,950 | -8,650 | -1,500 |
| Premiums and accounts receivable | 104,840 | 124,810 | 164,225 | 97,867 |
| Risk adjustment transfer receivable | 27,802 | 22,838 | 22,347 | 11,587 |
| Reinsurance recoverable | -132,146 | -98,839 | -103,990 | 32,123 |
| Other assets | 29,759 | 26,512 | 13,265 | 15,127 |
| Benefits payable | 207,665 | 194,902 | 108,848 | 390,740 |
| Unearned premiums | 2,727 | -4,900 | -3,492 | 211 |
| Premium deficiency reserve | 0 | 0 | 0 | -4,332 |
| Accounts payable and other liabilities | 111,598 | 141,608 | 199,627 | 118,079 |
| Reinsurance payable | -34,071 | -27,966 | -17,703 | -9,907 |
| Risk adjustment transfer payable | 212,964 | 1,088,846 | 396,110 | 26,938 |
| Net cash provided by operating activities | 422,951 | 1,387,609 | 878,542 | 631,373 |
| Purchase of investments | 780,673 | 607,838 | 336,869 | 2,023,049 |
| Sale of investments | 134,231 | 15,761 | 15,761 | 21,188 |
| Maturity and paydowns of investments | 478,173 | 267,419 | 155,906 | 663,011 |
| Purchase of property, equipment and capitalized software | 27,310 | 18,303 | 9,026 | 21,078 |
| Change in restricted deposits | -3,225 | -526 | 0 | -3,942 |
| Net cash used in investing activities | -192,354 | -342,435 | -174,228 | -1,355,986 |
| Proceeds from long-term debt | 410,000 | - | - | - |
| Payments of debt issuance costs | 22,677 | - | - | - |
| Purchase of capped calls related to convertible senior subordinated notes | 34,440 | - | - | - |
| Proceeds from joint venture contribution | - | - | - | 0 |
| Tax payments related to net settlement of share-based awards | 4,035 | 2,289 | 855 | - |
| Proceeds from exercise of stock options | 42,192 | 29,295 | 5,728 | 64,571 |
| Net cash provided by financing activities | 391,040 | 27,006 | 4,873 | 64,571 |
| Increase (decrease) in cash, cash equivalents and restricted cash equivalents | 621,637 | 1,072,180 | 709,187 | -660,042 |
| Cash and cash equivalents at beginning of period | 1,551,118 | 1,551,118 | 1,551,118 | 1,891,971 |
| Cash and cash equivalents at end of period | 2,172,755 | 2,623,298 | 2,260,305 | 1,231,929 |
Oscar Health, Inc. (OSCR)
Oscar Health, Inc. (OSCR)